Following Q3 results, Oppenheimer analyst Shaul Eyal says Splunk continues to generate "strong momentum." The analyst believes the company is in the early stages of its growth trajectory and should be able to maintain high revenue growth rates for several quarters to come. Further, Eyal thinks Splunk's profitability ratios reflect its tilt toward growth, and expects improved profitability measures as the company matures and profitability assumes a greater role in its strategic plan. He reiterates an Outperform rating and $80 price target on the shares.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).